German Merck KGaA Says FDA Seeks More Data On Rebif

February 6, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

FRANKFURT, Feb 6 (Reuters) - German Merck KGaA said on Tuesday a U.S. regulator has asked for more data on a new formulation of its multiple sclerosis drug Rebif, a move that could delay approval for the drug to come to the market.

>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe